aflibercept 8 mg
Sponsors
Regeneron Pharmaceuticals, Yeungnam University College of Medicine, Nantes University Hospital, Qilu Pharmaceutical Co., Ltd.
Conditions
Diabetic Macular EdemaDiabetic Macular Edema (DME)Exudative Age-Related Macular DegenerationNeovascular Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)Neovascular Age-related Macular Degeneration (nAMD)Polypoidal Choroidal VasculopathyPolypoidal Choroidal Vasculopathy (PCV)
Phase 3
A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Active, not recruitingNCT06491914
Start: 2024-07-24End: 2027-01-07Updated: 2026-09-18
Prospective Trial of the Efficacy and Safety of a Personalized Regimen of High-dose Aflibercept 8mg on Treatment-naive Polypoidal Choroidal Vasculopathy: the PALLAS Trial
RecruitingNCT07389980
Start: 2026-12-24End: 2028-12-01Target: 50Updated: 2026-02-05
A Clinical Study of QL1207H Injection Versus Aflibercept for Neovascular Age-related Macular Degeneration
Not yet recruitingNCT07489586
Start: 2026-03-01End: 2027-08-01Target: 356Updated: 2026-03-24
Unknown Phase
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
WithdrawnNCT06398080
Start: 2024-12-12End: 2029-01-03Updated: 2024-11-25
Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration
RecruitingNCT07423429
Start: 2026-02-20End: 2026-10-20Target: 100Updated: 2026-06-25